The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

Several companies have announced new executives and board members appointments as they prepare for growth in 2025.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Eyebright Medical's Loong Crystal PR IOL received Class III certification from China's NMPA, indicating high regulatory ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.

Himani Goyal, MD, explores a case of glaucoma treated with an intracameral implant, evaluating its efficacy in managing intraocular pressure and its role in optimizing long-term glaucoma care.

Himani Goyal, MD, discusses a case of cataracts and minimally invasive glaucoma surgery (MIGS) combination, highlighting the benefits of this approach in managing both cataracts and glaucoma in a ...

ViGeneron GmbH, a clinical-stage gene therapy company based in Munich, Germany, shared details of two new milestones in an ...

These resources include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, ...